Premium
Can drugs induce or aggravate sleep apneas? A case–noncase study in VigiBase ® , the WHO pharmacovigilance database
Author(s) -
Linselle Mélanie,
Sommet Agnès,
BondonGuitton Emmanuelle,
Moulis Florence,
Durrieu Geneviève,
Benevent Justine,
Rousseau Vanessa,
Chebane Leila,
Bagheri Haleh,
Montastruc François,
Montastruc JeanLouis
Publication year - 2017
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12264
Subject(s) - pharmacovigilance , medicine , database , pharmacology , meddra , drug reaction , drug , anesthesia , computer science
Abstract The potential favorizing role of drugs in sleep apnea syndrome ( SAS ) is unknown. This study investigates drugs associated with SAS in a pharmacovigilance database. SAS recorded as adverse drug reactions ( ADR s) in VigiBase ® , the WHO pharmacovigilance database (more than 11 million reports), from 1978 to 2015 was selected. The risk of SAS reports was estimated using the case–noncase method, with cases being SAS and noncases all other recorded ADR s. During this 37‐year period, 3325 ADR s including the word SAS were registered (0.05% of the database). Mean age was 51.2 ± 16.9 years with 52% men. ADR s were ‘serious’ in around 82% of cases. The case–noncase study found an association between SAS and exposition with sodium oxybate, rofecoxib, quetiapine, and clozapine for individual drugs and coxibs, antipsychotics, benzodiazepines, and opium alkaloids for drug classes. The potential role of other drugs is discussed. This study suggests that SAS can be associated with some drugs (mainly psychotropics) that are able to reveal or aggravate such a disease. Physicians should take into account the role of drugs in the etiological appraisal and management of SAS .